These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10613749)

  • 1. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance.
    Xiong X; Yang H; Westland CE; Zou R; Gibbs CS
    Hepatology; 2000 Jan; 31(1):219-24. PubMed ID: 10613749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.
    Xiong X; Flores C; Yang H; Toole JJ; Gibbs CS
    Hepatology; 1998 Dec; 28(6):1669-73. PubMed ID: 9828233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.
    Gutfreund KS; Williams M; George R; Bain VG; Ma MM; Yoshida EM; Villeneuve JP; Fischer KP; Tyrrel DL
    J Hepatol; 2000 Sep; 33(3):469-75. PubMed ID: 11020004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance.
    Pichoud C; Seignères B; Wang Z; Trépo C; Zoulim F
    Hepatology; 1999 Jan; 29(1):230-7. PubMed ID: 9862871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
    Ono SK; Kato N; Shiratori Y; Kato J; Goto T; Schinazi RF; Carrilho FJ; Omata M
    J Clin Invest; 2001 Feb; 107(4):449-55. PubMed ID: 11181644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
    Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
    J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
    León P; Pozo F; Echevarría JM
    Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
    Tillmann HL; Trautwein C; Bock T; Böker KH; Jäckel E; Glowienka M; Oldhafer K; Bruns I; Gauthier J; Condreay LD; Raab HR; Manns MP
    Hepatology; 1999 Jul; 30(1):244-56. PubMed ID: 10385663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
    Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
    Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.
    Aye TT; Bartholomeusz A; Shaw T; Bowden S; Breschkin A; McMillan J; Angus P; Locarnini S
    J Hepatol; 1997 May; 26(5):1148-53. PubMed ID: 9186847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy.
    Stuyver L; Van Geyt C; De Gendt S; Van Reybroeck G; Zoulim F; Leroux-Roels G; Rossau R
    J Clin Microbiol; 2000 Feb; 38(2):702-7. PubMed ID: 10655370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
    Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
    J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.
    Günther S; von Breunig F; Santantonio T; Jung MC; Gaeta GB; Fischer L; Sterneck M; Will H
    J Hepatol; 1999 May; 30(5):749-54. PubMed ID: 10365797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives for the treatment of hepatitis B virus infections.
    De Clercq E
    Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.
    Seignères B; Pichoud C; Ahmed SS; Hantz O; Trépo C; Zoulim F
    J Infect Dis; 2000 Apr; 181(4):1221-33. PubMed ID: 10762559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
    Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
    Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
    Delaney WE; Edwards R; Colledge D; Shaw T; Torresi J; Miller TG; Isom HC; Bock CT; Manns MP; Trautwein C; Locarnini S
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1705-13. PubMed ID: 11353615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.
    Melegari M; Scaglioni PP; Wands JR
    Hepatology; 1998 Feb; 27(2):628-33. PubMed ID: 9462667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.